目的：观察芪参茯苓方治疗慢性心力衰竭（CHF）阳虚血瘀证的疗效。方法：回顾性收集2019年3月至2023年9月281例CHF阳虚血瘀证患者的临床资料，依据患者治疗药物分为三组：西药组140例（仅接受西医常规治疗）；芪苈强心胶囊组79例（芪苈强心胶囊联合西医常规治疗1个月）；芪参茯苓方组62例（芪参茯苓方联合西医常规治疗1个月），比较三组的临床疗效及中医证候积分、脑钠肽（BNP）、肌钙蛋白I(cTnI)、左室射血分数（LVEF）和心力衰竭再住院率指标，并用Logistic回归分析筛选出临床有效的独立影响因素。观察并统计治疗期间不良反应发生情况。结果：芪参茯苓方组和芪苈强心胶囊组临床疗效总有效率大于西药组（P<0.05），中医证候积分低于西药组（P<0.05），同组内治疗前后比较，差异有统计学意义（P<0.01）。芪参茯苓方组LVEF和心力衰竭再住院率低于治疗前及其他两组（P<0.05）。三组的BNP、cTnI水平治疗前后组间比较，差异均无统计学意义（P>0.05）,Logistic回归分析表明，使用芪参茯苓方临床疗效高于其他两组（P<0.05）。各组均未见明显不良事件。结论：芪参茯苓方联合西医常规治疗对CHF阳虚血瘀证的疗效确切，对心功能和心衰症状有明显改善，且无明显不良反应。

Objective:To observe the effectiveness of Qishen Fuling Formula（芪参茯苓方）in the treatment of chronic heart failure(CHF) of yang deficiency and blood stasis type. Methods:From March 2019 to September 2023,clinical data of 281 CHF patients with yang deficiency and blood stasis type was obtained retrospectively. Patients were divided into 3 groups according to the medications:140 cases in the western medicines group(routine western medicine therapy only);79 cases in the Qili Qiangxin Capsule（芪苈强心胶囊） group(Qili Qiangxin Capsule with routine western medicine therapy for one month);and 62 cases in the Qishen Fuling Formula group(Qishen Fuling Formula with routine western medicine therapy for one month). The clinical efficacy and its effects on traditional Chinese medicine(TCM) syndrome score,brain natriuretic peptide(BNP),carcliac troponin Ⅰ（c TnⅠ）,left ventricular ejection fraction(LVEF),and the heart failure rehospitatization rate. indicators of the three groups were compared,and the independent factors that were clinically effective were determined using Logistic regression analysis. Observe and record the occurrence of adverse reactions during treatment. Results:The Qili Qiangxin Capsule group and Qishen Fuling Formula group both had higher overall clinical effective rates than the western medicine group(P<0.05),and showed more obvious decrease of TCM syndrome score than the western medicine group(P<0.05). The difference before and after treatment within the same group was statistically significant(P<0.01). The Qishen Fuling Formula group was better than pre-treatment and the other two groups in terms of both heart failure rehospitalization rate decrease and LVEF elevation(P<0.05). There was no difference in the between-group comparison of BNP and c Tn I levels before and after treatment in the three groups(P>0.05). The Qili Qiangxin Capsule group and Qishen Fuling Formula group both had better clinical efficacy than the western medicine group(P<0.05). Conclusions:Qishen Fuling Formula combined with routine western medicine showed better effect for CHF of yang deficiency and blood stasis type,and can improve the heart function and symptoms of heart failure obviously without obvious adverse reactions.